DCGI Gives Emergency Approval Of DRDO-developed Anti-Covid O
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The Institute of Nuclear Medicine and Allied Sciences (Inmas) in collaboration with Dr Reddy’s Laboratories, Hyderabad, developed an anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG). The third phase of the clinical trial results has shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in patients infected with the coronavirus. 2-DG is being developed to fight SARS-CoV-2 virus and inhibits viral growth. Phase-II clinical trial of 2-G in Covid-19 patients is set to begin in May 2020. Prime Minister Narendra Modi had called for preparedness against the pandemic.

In Phase-II trials (including dose ranging) conducted between May and October 2020, the drug was found to be safe in Covid-19 patients. Phase IIa was conducted in 6 hospitals and Phase IIb clinical trial was conducted at 11 hospitals. Patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints.

Based on successful results, the DCGI then permitted phase III of clinical trials in November 2020. It was conducted on 220 patients between December 2020 and March 2021. "In 2-DG arm significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SOC, indicating an early relief from Oxygen therapy/dependence. A similar trend was observed in patients more than 65 years also," the DRDO official said.

The DCGI had on May 1 granted permission for emergency use of the drug as an adjunct therapy in moderate to severe Covid-19 patients. Being a generic molecule and analog of glucose, it can be easily produced and made available in plenty in the country, the DRDO said. The drug comes in a sachet in the form of powder which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. The selective accumulation in virally infected cells makes this drug unique.

Source:
https://www.hindustantimes.com/india-news/dcgi-gives-emergency-approval-of-drdo-developed-anti-covid-oral-drug-101620461286695.html
J●y P●●●●r and 33 others like this14 shares
Like
Comment
Share
A●●●●g B●●●●●●m
A●●●●g B●●●●●●m General Medicine
Any protocols how to uses it ?
May 18, 2021Like
A●●●●g B●●●●●●m
A●●●●g B●●●●●●m General Medicine
Any protocols how to uses it ?
May 18, 2021Like
S●●●●a ?
S●●●●a ? General Medicine
Will it prevent mucormycosis occurance
May 21, 2021Like